When was THERAtRAME founded?

THERAtRAME was founded in 2022.

Where is THERAtRAME located?

THERAtRAME is headquartered in Liege, Belgium.

How many employees does THERAtRAME have?

As of May 31, 2026, the latest employee count at THERAtRAME is 16.

Is THERAtRAME a funded company?

THERAtRAME is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does THERAtRAME rank among its competitors?

THERAtRAME ranks 2247th amongst 3239 active competitors, of which 1113 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Senti Bio, which secured $40M in May, 2026.

Who are the top competitors of THERAtRAME?

THERAtRAME's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Senti Bio secured the most recent funding round in May, 2026.

THERAtRAME - 2026 Company Profile, Team, Funding & Competitors

THERAtRAME is a funded company based in Liege (Belgium), founded in 2022 by Pierre Close and Francesca Rapino. It operates as a Developer of therapeutics for cancer treatment. The company has 3239 active competitors, including 1113 funded and 771 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of therapeutics for cancer treatment. It offers s small molecules inhibitors targeting the tRNA epitranscriptomics for the treatment of cancer.

Website: www.theratrame.com/
Email ID: *****@theratrame.com

Key Metrics

Founded Year

2022

Location

Liege, Belgium

Stage

Funding Raised

Investors

Qbic Fund

Ranked

2247^th among 3239 active competitors

Employee Count

16 as on May 31, 2026

Similar Companies

Jazz Pharmaceuticals & 2969 more

View THERAtRAME's full profile

THERAtRAME is a funded company. THERAtRAME has 1 institutional investor.

View details of THERAtRAME's funding rounds and investors

The founders of THERAtRAME are Pierre Close and Francesca Rapino.

Here are the details of THERAtRAME's key team members:

Pierre Close: Co-Founder & CSO of THERAtRAME.
Contact Info: 1 email address
Francesca Rapino: Co-Founder & COO of THERAtRAME.

View details of THERAtRAME's Founder profiles and Board Members

THERAtRAME's employee count trend

THERAtRAME has 16 employees as of May 26. Here is THERAtRAME's employee count trend over the years:

Uncover THERAtRAME's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of THERAtRAME include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of THERAtRAME, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
4th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
2247th	THERAtRAME 2022, Liege (Belgium), Funding Raised	Developer of therapeutics for cancer treatment	-	Qbic Fund	26/100